| Study Name | Eligibility | Send Info |
| Adolescent Bariatric Study | Aged between 15 years 9 months and 18
Obesity with a BMI >35
Diagnosed with either pre-diabetes or type 2 diabetes |
|
| Ankylosing Spondylitis/Axial Spondyloarthritis | Age 18 years or older, have diagnosed Axial Spondyloarthritis |
|
| BRII-179-835-001 (Ph2 HBV Combo study) | Age 18 – 60 years and have Chronic Hepatitis B infection |
|
| Chronic Hepatitis B | Age 18 – 65 years and have Chronic Hepatitis B infection |
|
| CKD / Type 2 Diabetes | Are you aged ≥18 ≤79?
Have been receiving stable treatment for your diabetes and diabetic kidney disease for the past 3 months?
Are you able to participate in a study for up to 26 weeks? |
|
| DeLIVER | Are you aged between 22 and 70?
Have you been diagnosed with Type 2 Diabetes?
Are you on a consistent drug regimen of Metformin or Metformin/Vildagliptin only?
Do you have a waist circumference ≥102 cm (male) and ≥88 cm (female)?
Have you been diagnosed with hypertension:SBP ≥140 mmHg OR on ≤2 hypertension medications with SBP ≥130 mmHg? |
|
| IMG-7289-CTP-201 | Age over 18
Diagnosis of Essential Thrombocythemia
Failure of standard therapy, e.g. Hydroxyurea |
|
| KER-050 Anemia in MDS | Age over 18
Diagnosed with Myelodysplastic syndrome
Anemia |
|
| Maneuver (CSL346_2001) | Aged 25 years and older
Current diagnosis of Type 2 Diabetes |
|
| Momentum (SRA-MMB-301) | Age over 18, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis, Previously treated with Ruxolitinib |
|
| PACE | Aged between 40 and 85 years
Diagnosed with COPD
Have an a COPD exacerbation requiring OCS and/or antibiotics wihtin the last 12 months
A history of cardiovascular disease, including heart failure, ischaemic heart disease, tachyarrhythmias, and hypertension |
|
| Piranga [WV41073 (CHB)] | Aged 18 to 65
Chronic Hepatitis B infection
On stable NUC treatment (e.g Entecavir orTenofovir) |
|
| Polypill Active | Aged 18 years or older, hypertensive, no more than 3 current blood-pressure lowering medications. |
|
| Resveratrol | Aged over 18 years
Confirmed diagnosis of bronchiectasis within 5 years
Pulmonary exacerbation requiring antibiotics in the past 12 months |
|
| RSV OA Trial | Aged 60 or older, healthy or medically stable, and yet to recieve an annual influenza vaccine? |
|
| RSV Trial | Age 18 - 49 years with an uncomplicated, singleton pregnancy with no known increased risk for complications, no history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to a previous vaccine, pre pregnancy body mass index (BMI) < 40 kg/m^2 |
|
| RSV Trial | Baby born after October 2020, at 35 weeks gestation or above |
|
| Select - GCA (M16-852) | Age 50 years or older, have diagnosed Giant Cell Arthritis, headache/jaw pain/vision loss, shoulder and/or hip pain |
|
| Type 2 Diabetes/Chronic Kidney Disease | Age between 18-75
Diabetic Kidney Disease
Type 2 Diabetes |
|
| Ulcerative colitis | Age less than 65 years, have diagnosed ulcerative colitis and experiencing increase in daily stool frequency and/or rectal bleeding, no allergy to antibiotic vancomycin, willing to undergo two colonoscopy procedures as part of the study (3 months apart) |
|